Skip to main content

Advertisement

SpringerLink
Log in

Safety of biologics approved for treating rheumatoid arthritis: analysis of spontaneous reports of adverse events

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Despite the effectiveness of biologics approved for the treatment of rheumatoid arthritis, they have been associated with serious adverse events (AEs). Biologics are used under close supervision of health care professionals. In Portugal, they are legally required to report AEs occurring during the treatment. This study aims at investigating post-marketing safety monitoring data of biologics in Portugal by comparing the frequency of spontaneously reported adverse events between 2009 and 2011 with the frequency of such events in the summary of the product characteristics of each biologic. Sales data for biologics were obtained from IMS Health and converted into defined daily doses/1,000 inhabitants/day in order to estimate a proportion of the population treated. The frequency of AEs was estimated as the percentage of patients in which an AE may have occurred. The use of each biologic was estimated for adalimumab at 1,439 patients/year, etanercept 1,944 patients/year, and infliximab 3,211 patients/year. A total of 992 AEs were reported: 207 for adalimumab, 199 for etanercept, and 586 for infliximab. Of the 515 different spontaneously reported AEs, 194 were included for comparisons with the SPCs. Of those, 31 (16 %) were similarly frequent, and 163 (84.0 %) occurred less frequently compared with SPCs’ data. These results suggest an insufficient post-marketing safety monitoring of biologics in Portugal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Keyser FD (2011) Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev 7(1):77–87

    Article  PubMed  Google Scholar 

  2. Woodrick RS, Ruderman EM (2011) Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol 7(11):639–652

    Article  CAS  PubMed  Google Scholar 

  3. Singh JA, Wells GA, Christensen R, et al. (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview (review). Cochrane Database of Systematic Reviews Issue 2. Art. No. CD008794. doi: 10.1002/14651858.CD008794.pub2

  4. Moore TJ, Cohen MR, Furberg CD (2007) Serious adverse drug events reported to the Food and Drug Administration, 1998–2005. Arch Intern Med 167(16):1752–1759

    Article  PubMed  Google Scholar 

  5. Giezen TJ, Mantel-Teeuwisse AK, Meyboom RH et al (2010) Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Drug Saf 33(10):865–878

    Article  PubMed  Google Scholar 

  6. Colmegna I, Ohata BR, Menard HA (2012) Current understanding of rheumatoid arthritis therapy. Clin Pharmacol Ther 91(4):607–620

    Article  CAS  PubMed  Google Scholar 

  7. Keystone EC (2011) Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis? A review of long term data. J Rheumatol 38(8):1552–1562

    Article  CAS  PubMed  Google Scholar 

  8. Madre LK, Califf RM, Reynolds RF et al (2006) Views from academia, industry, and regulatory agencies. In: Strom BL, Kimmel SE (eds) Textbook of pharmacoepidemiology. Wiley, Chichester, pp 63–88

    Google Scholar 

  9. Davis S, King B, Raine JM (2007) Spontaneous reporting—UK. In: Mann RD, Andrews EB (eds) Pharmacovigilance, 2nd edn. Wiley, Chichester, pp 199–215

    Google Scholar 

  10. Commission of European Communities (2003) Commission Directive 2003/63/EC of 25 June 2003 Amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use [online]. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/dir_2003_63/dir_2003_63_en.pdf. Accessed 17 Jan 2013

  11. Commission of European Communities (2009) A guideline on summary of product characteristics, September 2009, in The Rules Governing Medicinal Products in the European Union, Volume 2C Notice to Applicants [online]. Available from: http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf. Accessed 6 Mar 2013

  12. World Health Organization Collaborating Centre for Drug Statistics Methodology (2012) ATC/DDD Index 2012. Available from: http://www.whocc.no/atc_ddd_index/. Accessed 3 Dec 2012

  13. Inc P (2012) Enbrel (etanercept). EU summary of product characteristics. Pfizer, New York

    Google Scholar 

  14. National Institute of Statistics (2012) Statistics Portugal. Available from: http://www.ine.pt. Accessed 3 Dec 2012

  15. World Health Organization (2003) Drug utilization metrics and their applications. Introduction to drug utilization research. Oslo. Available from: http://www.whocc.no/filearchive/publications/drug_utilization_research.pdf. Accessed 17 Jan 2013

  16. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (2013) Medical Dictionary for Regulatory Activities (MedDRA). Available from: http://www.ich.org/products/meddra.html. Accessed 27 Feb 2013

  17. Maintenance and Support Services Organization (MSSO) (2013) Medical Dictionary for Regulatory Activities (MedDRA). Available from: http://www.meddramsso.com/. Accessed 27 Feb 2013

  18. World Health Organization Criteria for Serious Adverse Event or Reaction [WWW document] (2011) Available from: http://who-umc.org/Graphics/24729.pdf. Accessed 17 Jan 2013

  19. Ltd AV (2012) Humira (adalimumab). EU summary of product characteristics. AbbVie, Maidenhead

    Google Scholar 

  20. Jansen Biologics BV (2012) Remicade (infliximab). EU summary of product characteristics. Jansen Biologics BV, Leiden

    Google Scholar 

  21. INFARMED (2012) Casos de RAM notificados ao SNF. Available from: http://www.infarmed.pt/portal/page/portal/INFARMED/MEDICAMENTOS_USO_HUMANO/FARMACOVIGILANCIA/NOTIFICACAO_DE_RAM/Casos%20de%20RAM%20recebidos%20no%20SNF.pdf. Accessed 17 Jan 2013

  22. Zochling J, Maxwell L, Beardmore J, Boonen A (2009) TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database of Systematic Reviews Issue 1. doi:10.1002/14651858.CD005468

  23. Behm BW, Bickston SJ (2008) Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database of Systematic Reviews Issue 1. doi:10.1002/14651858.CD006893

  24. Agbabiaka TB, Savovic J, Ernst E (2008) Methods for causality assessment of adverse drug reactions—a systematic review. Drug Saf 31(1):21–37

    Article  PubMed  Google Scholar 

  25. Brajovic S, Piazza-Hepp T, Swartz L, Dal Pan G (2012) Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration. Pharmacoepidemiol Drug Saf 21(6):565–570

    Article  PubMed  Google Scholar 

  26. Kerbleski JF, Gottlieb AB (2009) Dermatological complications and safety of anti-TNF treatments. Gut 58(8):1033–1039

    Article  CAS  PubMed  Google Scholar 

  27. Furst DE (2010) The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 39(5):327–346

    Article  CAS  PubMed  Google Scholar 

  28. Aronson JK, Ferner RE (2005) Clarification of terminology in drug. Drug Saf 28(10):851–870

    Article  PubMed  Google Scholar 

  29. Evans S (2007) Statistical methods of signal detection. In: Mann RD, Andrews EB (eds) Pharmacovigilance, 2nd edn. Wiley, Chichester, p 251

    Google Scholar 

Download references

Acknowledgments

The authors would like to thank IMS Health Portugal, INFARMED – National Authority of Medicines and Health Products IP, Merck Sharp & Dohme, and Pfizer for the supplied data.

Disclosures

None.

Author information

Authors and Affiliations

  1. HTA - Health Technology Assessment Centre, AIBILI - Association for Innovation and Biomedical Research on Light, Azinhaga de Santa Comba, Celas 3000-548, Coimbra, Portugal

    Diogo Mendes, Carlos Alves & Francisco Batel Marques

  2. School of Pharmacy, University of Coimbra, Coimbra, Portugal

    Carlos Alves & Francisco Batel Marques

  3. Health Sciences Research Centre (CICS-UBI), University of Beira Interior, Covilhã, Portugal

    Carlos Alves

Authors
  1. Diogo Mendes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlos Alves
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francisco Batel Marques
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Diogo Mendes.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOCX 23 kb)

ESM 2

(DOCX 50 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mendes, D., Alves, C. & Batel Marques, F. Safety of biologics approved for treating rheumatoid arthritis: analysis of spontaneous reports of adverse events. Clin Rheumatol 32, 1207–1214 (2013). https://doi.org/10.1007/s10067-013-2256-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-013-2256-9

Keywords

Search

Navigation